Ratio Therapeutics

Ratio Therapeutics announced $70M in Series C financing on July 31, 2026. Ratio Therapeutics closed a $70 million Series C financing with existing and new investors and expects to use the funding to advance its ongoing ATLAS study and move its next-generation RLT candidate into the clinic.

Round details

The financing includes backing from Duquesne Family Office, Bristol Myers Squibb, Catalio Capital Management, Eli Lilly and Company, Wasatch Group. The company did not publish a valuation with the announcement.

• Round: Series C
• Capital announced: $70M
• Total funding reported: $240M+

How the company plans to use the capital

Ratio Therapeutics said it expects to use the funding to advance its ongoing ATLAS study of its lead radiotherapeutic asset [Ac-225]RTX-2358 in advanced sarcomas and to move its next-generation RLT candidate into the clinic. It also plans to expand its discovery pipeline into new oncology targets and scale its manufacturing capabilities.

Why this matters for GTM teams

The round included existing investors Duquesne Family Office and Bristol Myers Squibb and new investors Catalio Capital Management, Eli Lilly and Company and Wasatch Group, and brought total capital raised to over $240 million.

Fresh capital is often an operational signal rather than a buying signal by itself. Teams should validate the company’s hiring pattern, product launches, geographic expansion, and technology priorities before choosing the message and timing of outreach.

Source and methodology

This report is based on the company’s announcement and records the disclosed amount, round, investors, location, and stated use of funds. SalesTools Research does not estimate undisclosed valuation or revenue figures.

Primary source: Ratio Therapeutics Series C announcement.